World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
134
Citations
91710
World Ranking
2106
National Ranking
1190

James T. Willerson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James T. Willerson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 986 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James T. Willerson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James T. Willerson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 134 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2006 - Libin/AHFMR Prize in Cardiovascular Research
  • 2003 - Distinguished Scientist Award, American Heart Association
  • 2000 - Distinguished Fellowship Award, American College of Cardiology (ACC)
  • 1997 - Member of the National Academy of Medicine (NAM)
  • 1992 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

James T. Willerson was affiliated with The University of Texas Health Science Center at Houston in the United States. Their research spanned multiple fields, primarily Medicine and Biochemistry, Genetics and Molecular Biology. Key subfields of study included Molecular Biology, Genetics, Cardiology and Cardiovascular Medicine, Surgery, and Cell Biology.

The scientist's main topics of work covered several aspects of cardiovascular research and regenerative medicine. These topics comprised:

  • Mesenchymal stem cell research
  • Hippo pathway signaling and YAP/TAZ
  • Congenital heart defects research
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Cardiac Structural Anomalies and Repair
  • Muscle Physiology and Disorders
  • Tissue Engineering and Regenerative Medicine

Among recent papers authored or co-authored by James T. Willerson were:

  • A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial, 2021, European Journal of Heart Failure
  • Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction, 2021, Science Translational Medicine
  • Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients, 2020, JACC CardioOncology
  • Left Ventricular Noncompaction Detected by Cardiac Magnetic Resonance Screening: A Reexamination of Diagnostic Criteria, 2020, Texas Heart Institute Journal
  • Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies, 2021, ESC Heart Failure

Frequent co-authors included:

  • Emerson C. Perin
  • Roberto Bolli
  • Jay H. Traverse
  • Joshua M. Hare
  • Carl J. Pepine

James T. Willerson had multiple publications in notable venues such as:

  • UNC Libraries
  • Texas Heart Institute Journal
  • European Journal of Heart Failure
  • Science Translational Medicine
  • JACC CardioOncology

The scientist received several awards throughout their career, including:

  • Libin/AHFMR Prize in Cardiovascular Research, 2006
  • Distinguished Scientist Award, American Heart Association, 2003
  • Distinguished Fellowship Award, American College of Cardiology (ACC), 2000
  • Member of the National Academy of Medicine (NAM), 1997
  • Fellow of the American Association for the Advancement of Science (AAAS), 1992
  • Member of the Association of American Physicians

Best Publications

  • Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

    Paul M. Ridker;Eleanor Danielson;Francisco A. H. Fonseca;Jacques Genest

  • From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

    Morteza Naghavi;Peter Libby;Erling Falk;S. Ward Casscells;S. Ward Casscells

  • Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells

    Vincenzo Pasceri;Vincenzo Pasceri;James T. Willerson;James T. Willerson;Edward T. H. Yeh

  • Circadian variation in the frequency of onset of acute myocardial infarction

    J. E. Muller;P. H. Stone;Z. G. Turi;J. D. Rutherford

  • Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

    Eugene S. Chung;Milton Packer;Kim Hung Lo;Adedigbo A. Fasanmade

  • Inflammation as a cardiovascular risk factor.

    James T. Willerson;Paul M. Ridker

  • Appointment of New Associate Editor for Circulation

    James T. Willerson

  • Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs

    Vincenzo Pasceri;Vincenzo Pasceri;Jed Chang;James T. Willerson;James T. Willerson;Edward T. H. Yeh

  • The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis

    Timothy D. Henry;Brian H. Annex;George R. McKendall;Michael A. Azrin

  • Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

    Paul M Ridker;Eleanor Danielson;Francisco Ah Fonseca;Jacques Genest

  • Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

    J. H. Chesebro;G. Knatterud;R. Roberts;J. Borer

  • Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

    EJ Topol;AM Lincoff;RM Califf;EM Ohman

  • A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism

    Robert J. Glynn;Eleanor Danielson;Francisco A.H. Fonseca;Jacques Genest

  • Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

    P. D. Hirsh;L. D. Hillis;W. B. Campbell;B. G. Firth

  • Leukocyte count and coronary heart disease: Implications for risk assessment

    Mohammad Madjid;Mohammad Madjid;Imran Awan;Imran Awan;James T. Willerson;James T. Willerson;S. Ward Casscells;S. Ward Casscells;S. Ward Casscells

  • Risk factors for sudden death after acute myocardial infarction: Two-year follow-up☆

    Jhulan Mukharji;Robert E Rude;W.Kenneth Poole;Nancy Gustafson

  • Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator–Activated Receptor-γ Activators

    Vincenzo Pasceri;Henry D. Wu;James T. Willerson;James T. Willerson;Edward T. H. Yeh

  • The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis☆

    Peter H. Stone;Peter H. Stone;James E. Muller;James E. Muller;Tyler Hartwell;Tyler Hartwell;B. J. York;B. J. York

  • Suppression of canonical Wnt/β-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy

    Eduardo Garcia-Gras;Raffaella Lombardi;Michael J. Giocondo;James T. Willerson

  • The Pathology of Vulnerable Plaque

    Renu Virmani;Allen P Burke;James T Willerson;Andrew Farb

Frequent Co-Authors

L. M. Buja
L. M. Buja The University of Texas Health Science Center at Houston
Edward T.H. Yeh
Edward T.H. Yeh University of Missouri
James E. Muller
James E. Muller Brigham and Women's Hospital
Pascal Nicod
Pascal Nicod University Hospital of Lausanne
William B. Campbell
William B. Campbell Medical College of Wisconsin
Kenneth R. Chien
Kenneth R. Chien Karolinska Institute
Richard A. Dixon
Richard A. Dixon University of North Texas
Eugene Braunwald
Eugene Braunwald Harvard Medical School
David R. Holmes
David R. Holmes Mayo Clinic
Eric Boerwinkle
Eric Boerwinkle The University of Texas Health Science Center at Houston

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of medicine offers diverse educational paths beyond becoming a doctor. For many, starting with a related online degree can open doors to rewarding careers in healthcare with increased flexibility and affordability.

Several allied health roles can be pursued entirely online. For those interested in healthcare administration, a low cost medical coding and billing online program provides specialized training to join hospitals, clinics, or insurance companies quickly and affordably.

Nursing remains one of the most in-demand professions in the USA. Prospective students can explore the cheapest online bsn programs to become registered nurses, or continue to the graduate level with the cheapest online np programs to become a nurse practitioner with greater autonomy and earning potential.

For nurses seeking leadership, research, or teaching roles, an online phd nursing can offer advanced career progression without the need to relocate or leave current employment.

These online programs provide flexibility for balancing work, family, and education, making healthcare careers accessible to more aspiring professionals.

Best Scientists Citing James T. Willerson

Recently Published Articles